Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
3 Bargain-Cheap Small Caps Worth a Second Look
Innoviva (NASDAQ:INVA) Shares Cross Above 200 Day Moving Average – Here’s What Happened
Analysts Set Innoviva, Inc. (NASDAQ:INVA) Price Target at $34.80
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (NASDAQ:INVA) Receives Average Recommendation of “Moderate Buy” from Brokerages
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SG Americas Securities LLC Raises Position in Innoviva, Inc. $INVA
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Boston Partners Boosts Holdings in Innoviva, Inc. $INVA
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Innoviva, Inc. $INVA
Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
New Strong Buy Stocks for October 10th
Are Investors Undervaluing Innoviva (INVA) Right Now?
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript
Innoviva to Participate in Upcoming Investor Conferences
Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Innoviva (INVA) Q2 Sales Jump 64%
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Innoviva to Participate in Upcoming Investor Conferences
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024